Myelin Basic Protein Binds to and Inhibits the Fibrillar Assembly of Aβ42 in Vitro
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The deposition of amyloid beta-protein (Abeta) fibrils into plaques within the brain parenchyma and along cerebral blood vessels is a hallmark of Alzheimer's disease. Abeta peptides are produced through the successive cleavage of the Abeta precursor protein by beta- and gamma-secretase, producing peptides between 39 and 43 amino acids in length. The most common of these are Abeta40 (the most abundant) and Abeta42. Abeta42 is more fibrillogenic than Abeta40 and has been implicated in early Abeta plaque deposition. Our previous studies determined that myelin basic protein (MBP) was capable of inhibiting fibril formation of a highly fibrillogenic Abeta peptide containing both E22Q (Dutch) and D23N (Iowa) mutations associated with familial forms of cerebral amyloid angiopathy [Hoos, M. D., et al. (2007) J. Biol. Chem. 282, 9952-9961]. In this study, we show through a combination of biochemical and ultrastructural techniques that MBP is also capable of inhibiting the beta-sheet fibrillar assembly of the normal Abeta42 peptide. These findings suggest that MBP may play a role in regulating the deposition of Abeta42 and thereby also may regulate the early formation of amyloid plaques in Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oakley, H., Cole, S. L., Logan, S., Maus, E., Shao, P., Craft, J., Guillozet-Bongaarts, A., Ohno, M., Disterhoft, J., Van Eldik, L., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.1202-06.2006 · Cited by 3,530 · cited 2×
“of brain cortical tissue from either human AD brain or one-yearold 5xFAD mice (28) was homogenized in 50 mM Tris (pH 7.”
Aβ Oligomers – a decade of discovery
Walsh, D. M., & Selkoe, D. J. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04426.x · Cited by 1,938
Amyloid β Protein Gene: cDNA, mRNA Distribution, and Genetic Linkage Near the Alzheimer Locus
Tanzi, R. E., Gusella, J. F., Watkins, P. C., Bruns, G. A. P., St George-Hyslop, P., Van Keuren, M. L., Patterson, D., Pagan, S., Kurnit, D. M., & Neve, R. L. (1987) · Science · doi:10.1126/science.2949367 · Cited by 1,611
In vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210207200 · Cited by 1,015 · cited 1×
“Aβ42 peptides were initially prepared in hexafluoroisopropanol, lyophilized, and resuspended in either dimethyl sulfoxide (Me2SO) or 100 mM NaOH as previously described (27).”
Assembly and aggregation properties of synthetic Alzheimer's A4/beta amyloid peptide analogs.
Burdick, D., Soreghan, B., Kwon, M., Kosmoski, J., Knauer, M., Henschen, A., Yates, J., Cotman, C., & Glabe, C. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48529-8 · Cited by 1,014
Alzheimer disease and cerebrovascular pathology: an update
Jellinger, K. A. (2002) · Journal of Neural Transmission · doi:10.1007/s007020200068 · Cited by 680 · cited 1×
“Cerebral amyloid angiopathy (CAA), a condition prevalently found in AD, is characterized by fibrillar Aβ deposition within and along primarily small and medium-sized arteries and arterioles of the cerebral cortex and leptomeninges and in the cerebral microvasculature (7, 11, 12).”
Aβ42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice
McGowan, E., Pickford, F., Kim, J., Onstead, L., Eriksen, J., Yu, C., Skipper, L., Murphy, M. P., Beard, J., Das, P., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.06.030 · Cited by 637 · cited 2×
“Many of these Aβ42WT oligomeric assemblies have been shown tobemore cytotoxic than Aβ40WT oligomeric assemblies (36-38) and to act as seeds for the formation of Aβ40WT fibrils (9).”
Grabowski, T. J., Cho, H. S., Vonsattel, J. P. G., Rebeck, G. W., & Greenberg, S. M. (2001) · Annals of Neurology · doi:10.1002/ana.1009 · Cited by 523
Thal, D. R., Ghebremedhin, E., Orantes, M., & Wiestler, O. D. (2003) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/62.12.1287 · Cited by 384 · cited 2×
“The most recognized example of familial CAA is the Dutch type resulting from an E22Q substitution in Aβ (13, 14, 19).”
DeKosky, S. T., Abrahamson, E. E., Ciallella, J. R., Paljug, W. R., Wisniewski, S. R., Clark, R. S. B., & Ikonomovic, M. D. (2007) · Archives of Neurology · doi:10.1001/archneur.64.4.541 · Cited by 152
Cited by
Association of Amyloid Pathology With Myelin Alteration in Preclinical Alzheimer Disease
Dean, D. C., Hurley, S. A., Kecskemeti, S. R., O’Grady, J. P., Canda, C., Davenport-Sis, N. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Asthana, S., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3232 · Cited by 252
“formation of amyloid plaques in parenchyma.(33,34) Therefore, the loss of myelin and decreases in concentrations of myelin basic proteinmay promote acceleratedAβ42 depositions and result in increasedamyloidplaque formation.”
The role of myelin damage in Alzheimer’s disease pathology
Papuć, E., & Rejdak, K. (2020) · Archives of Medical Science · doi:10.5114/aoms.2018.76863 · Cited by 188
“The myelin basic protein (MBP), which is an intracellular protein and a major structural protein component of myelin, has been proven to bind Aβ and inhibit Aβ fibril formation in AD, which possibly may have a regulatory role in the deposition of Aβ 42 and formation of amyloid plaques in the extracellular space of the…”
BackgroundFocal demyelination in Alzheimer’s disease and transgenic mouse models
Mitew, S., Kirkcaldie, M. T. K., Halliday, G. M., Shepherd, C. E., Vickers, J. C., & Dickson, T. C. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0657-2 · Cited by 186
Are amyloid-degrading enzymes viable therapeutic targets in Alzheimer’s disease?
Nalivaeva, N. N., Beckett, C., Belyaev, N. D., & Turner, A. J. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07510.x · Cited by 169
Ou-Yang, M.-H., & Van Nostrand, W. E. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-134 · Cited by 30
Metadata
- Authors
- Hoos, M. D., Ahmed, M., Smith, S. O., & Van Nostrand, W. E.
- Venue
- Biochemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2009-05-07
- Volume
- 48
- Issue
- 22
- Pages
- 4720-4727
- ISSN
- 0006-2960 (ISSN-L)
- 1520-4995
- OpenAlex
- W2062860547
- Cited by
- 34
- References
- 10
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.